Breaking News Instant updates and real-time market news.

PFE

Pfizer

$43.92

-1.05 (-2.33%)

04:55
12/10/18
12/10
04:55
12/10/18
04:55

Pfizer management to meet with Oppenheimer

Meeting to be held in New York on December 10 hosted by Oppenheimer.

  • 10

    Dec

  • 18

    Dec

PFE Pfizer
$43.92

-1.05 (-2.33%)

11/07/18
CHDN
11/07/18
NO CHANGE
Target $70
CHDN
Buy
uniQure price target raised to $70 from $50 at Chardan
Chardan analyst Gbola Amusa increased his price target on uniQure (QURE) to $70 from $50, stating that he believes the market is missing important dynamics in uniQure's favor over hemB competition from Pfizer (PFE) and Spark Therapeutics (ONCE). Amusa said uniQure's manufacturing is "much more scalable" than Pfizer's and he also believes uniQure's IP may cover the construct utilized by Pfizer. Amusa keeps a Buy rating on uniQure shares.
11/19/18
WELS
11/19/18
NO CHANGE
WELS
Pfizer price hikes may bring industry scrutiny, says Wells Fargo
Pfizer's (PFE) plans to raise prices on a host of medicines may put the drug industry "further in the crosshairs of an administration and Congress that is set on lowering drug prices," Wells Fargo analyst David Maris tells investors in a research note. The analyst points out that Pfizer earlier this year was criticized by the Trump administration for drug price increases, and as a result, it rolled the price increases back. However, Pfizer's new price increases "are not egregious" and its advance warning may be an attempt to see if minor price increases will also bring the administration's rebuke, says Maris. Nonetheless, given how public the administration's previous rebuke was, the analyst thinks Pfizer's confirmation Friday could "enflame the debate around drug pricing, especially since it comes less than two weeks following an election that resulted in Democrat control of the House with many having run on a drug-price-controls/Medicare-for-All platforms." Other large drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
11/19/18
CANT
11/19/18
NO CHANGE
Target $53
CANT
Overweight
Pfizer's oncology assets are underappreciated, says Cantor Fitzgerald
Pfizer's oncology assets will make up 13% of its total 2018 sales and they will accelerate the company's sales growth for the foreseeable future, but these drugs are underappreciated, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. Pfizer has said that through 2022 it expects 15 potential blockbusters to be launched, and oncology drugs are represented in these opportunities, the analyst points out. She sees upside to consensus estimates and keeps an Overweight rating on Pfizer with a $53 price target.
11/27/18
LEER
11/27/18
INITIATION
LEER
Leerink initiates select Genetic Medicine names on increasing regulatory clarity
Leerink analyst Mani Foroohar initiated select Genetic Medicine stocks, stating that the field is "is rich with companies developing drugs" to treat rare diseases and that he is increasingly more bullish on "innovation velocity and increasing regulatory clarity in the sector. Based on his "balanced view of pricing dynamics", the analyst issues an Outperform rating on Wave Life Sciences (WVE), Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Eidos Therapeutics (EIDX), Dicerna (DRNA) and Bluebird Bio (BLUE). The analyst likes Wave Life Sciences as a pure play on Oligotherapeutics and its stereopure chemistry platform as a differentiated approach to oligo drug design. Foroohar is positive on Rocket Pharma's lead assets in gene therapies for Fanconi Anemia and Leukocyte Adhesion Deficiency-I "which will likely be the company's first potential approved product." The analyst is positive on Intellia Therapeutics' "robust balance sheet to support development, trading at a material discount to closest comps peers". For Eidos, the analyst cites the prospects of its drug candidate for TTR amyloidosis currently in a placebo-controlled Phase 2 study that may offer a competitive profile relative to Pfizer's (PFE) tafamidis. For Dicerna, Foroohar notes that its DCR-PHXC "is an RNAi therapeutic that targets lactate dehydrogenase A for the treatment of all subtypes of Primary Hyperoxaluria vs. competitor Alnylam's (ALNY) lumasiran, which only treats PH Type 1. For Bluebird Bio, the analyst is positive on its position as a "leader in ex vivo gene therapy, with four programs with visibility towards near-term regulatory approval". Foroohar initiates Avrobio (AVRO), Alnylam (ALNY), and Ionis Pharmaceuticals (IONS) with Market Perform rating based on competitive launches for their products along with "mixed" early signs of their results. The analyst also rates Regenxbio (RGNX) at underperform, saying that its "current valuation more than accounts for robust royalty streams from sales in spinal muscular atrophy" and other partnered assets.

TODAY'S FREE FLY STORIES

VG

Vonage

$7.46

0.25 (3.47%)

, SAP

SAP

$135.56

0.59 (0.44%)

08:00
11/22/19
11/22
08:00
11/22/19
08:00
Hot Stocks
Vonage names former SAP executive as President of Applications Group »

Vonage (VG) announced…

VG

Vonage

$7.46

0.25 (3.47%)

SAP

SAP

$135.56

0.59 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 09

    Dec

EPAM

Epam Systems

$205.39

-3.04 (-1.46%)

08:00
11/22/19
11/22
08:00
11/22/19
08:00
Recommendations
Epam Systems analyst commentary  »

Epam Systems price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$262.04

-1.15 (-0.44%)

08:00
11/22/19
11/22
08:00
11/22/19
08:00
Options
Apple put buyer realizes 25% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:58
11/22/19
11/22
07:58
11/22/19
07:58
Conference/Events
FDA Blood Products Advisory Committee to hold a meeting »

The Committee discusses…

LGF.A

Lionsgate

$9.22

-0.28 (-2.95%)

, CMCSA

Comcast

$44.37

0.15 (0.34%)

07:56
11/22/19
11/22
07:56
11/22/19
07:56
Recommendations
Lionsgate, Comcast analyst commentary  »

Lionsgate price…

LGF.A

Lionsgate

$9.22

-0.28 (-2.95%)

CMCSA

Comcast

$44.37

0.15 (0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ROST

Ross Stores

$111.81

1.39 (1.26%)

07:55
11/22/19
11/22
07:55
11/22/19
07:55
Recommendations
Ross Stores analyst commentary  »

Ross Stores…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

ALNY

Alnylam

$111.26

3 (2.77%)

07:55
11/22/19
11/22
07:55
11/22/19
07:55
Conference/Events
Alnylam to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 07

    Dec

  • 04

    Feb

EPAM

Epam Systems

$205.39

-3.04 (-1.46%)

07:52
11/22/19
11/22
07:52
11/22/19
07:52
Recommendations
Epam Systems analyst commentary  »

Epam Systems price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAN

Anaplan

$53.00

3.84 (7.81%)

07:51
11/22/19
11/22
07:51
11/22/19
07:51
Recommendations
Anaplan analyst commentary  »

Anaplan exemplary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STZ

Constellation Brands

$186.57

0.75 (0.40%)

, CGC

Canopy Growth

$20.28

2.65 (15.03%)

07:51
11/22/19
11/22
07:51
11/22/19
07:51
Hot Stocks
Constellation plans no contributions to Canopy beyond exercise of warrants »

Constellation Brands…

STZ

Constellation Brands

$186.57

0.75 (0.40%)

CGC

Canopy Growth

$20.28

2.65 (15.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNPR

Juniper

$25.32

-0.24 (-0.94%)

07:51
11/22/19
11/22
07:51
11/22/19
07:51
Hot Stocks
Juniper announces milestone for longest 400GbE deployment »

Juniper Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 12

    Dec

ADSK

Autodesk

$165.15

-0.19 (-0.11%)

07:47
11/22/19
11/22
07:47
11/22/19
07:47
Recommendations
Autodesk analyst commentary  »

Autodesk should meet or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 02

    Dec

LOW

Lowe's

$116.96

-0.88 (-0.75%)

, HD

Home Depot

$218.56

-2.28 (-1.03%)

07:43
11/22/19
11/22
07:43
11/22/19
07:43
Recommendations
Lowe's, Home Depot analyst commentary  »

Lowe's price target…

LOW

Lowe's

$116.96

-0.88 (-0.75%)

HD

Home Depot

$218.56

-2.28 (-1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 11

    Dec

  • 25

    Feb

PZZA

Papa John's

$61.47

1.2 (1.99%)

07:42
11/22/19
11/22
07:42
11/22/19
07:42
Recommendations
Papa John's analyst commentary  »

Papa John's checks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

TSLA

Tesla

$354.82

2.49 (0.71%)

07:41
11/22/19
11/22
07:41
11/22/19
07:41
Recommendations
Tesla analyst commentary  »

Tesla pickup unveiled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRMK

Broadmark Realty Capital

$10.94

-0.02 (-0.18%)

07:40
11/22/19
11/22
07:40
11/22/19
07:40
Initiation
Broadmark Realty Capital initiated  »

Broadmark Realty Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:40
11/22/19
11/22
07:40
11/22/19
07:40
General news
Treasury Market Outlook: bond yields are modestly richer outside of Asia »

Treasury Market Outlook:…

NKSH

National Bankshares

$47.08

1.59 (3.50%)

07:39
11/22/19
11/22
07:39
11/22/19
07:39
Downgrade
National Bankshares rating change  »

National Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRPO

Precipio

$2.03

0.01 (0.50%)

07:37
11/22/19
11/22
07:37
11/22/19
07:37
Initiation
Precipio initiated  »

Precipio initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$288.66

3.68 (1.29%)

07:36
11/22/19
11/22
07:36
11/22/19
07:36
Hot Stocks
Biogen announces results from Phase 3 EVOLVE-MS-2 study »

Biogen announced detailed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

APDN

Applied DNA Sciences

$4.14

(0.00%)

07:35
11/22/19
11/22
07:35
11/22/19
07:35
Upgrade
Applied DNA Sciences rating change  »

Applied DNA Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$126.80

-0.04 (-0.03%)

07:35
11/22/19
11/22
07:35
11/22/19
07:35
Recommendations
Splunk analyst commentary  »

Splunk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

LYFT

Lyft

$46.77

2.92 (6.66%)

07:35
11/22/19
11/22
07:35
11/22/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 09

    Dec

ZM

Zoom Video

$69.91

-1.02 (-1.44%)

07:34
11/22/19
11/22
07:34
11/22/19
07:34
Initiation
Zoom Video initiated  »

Guggenheim starts Zoom…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 16

    Dec

CBWTF

Auxly Cannabis

$0.00

(0.00%)

07:33
11/22/19
11/22
07:33
11/22/19
07:33
Hot Stocks
Auxly says company 'ready to enter' Cannabis 2.0 market on first day of sales »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.